Cellular and molecular mechanisms of HGF/Met in the cardiovascular system

Clinical Science

Volumn 129, Issue 12, 2015, Pages 1173-1193

  Gallo, Simona ^a   Sala, Valentina ^a   Gatti, Stefano ^a   Crepaldi, Tiziana ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Angiogenesis; Cardioprotection; Fibrosis; HGF Met; Immunomodulation; Regeneration

Indexed keywords

ANGIOTENSIN II; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAC1 PROTEIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; AUTOIMMUNE DISEASE; AUTOPHAGY; BLOOD VESSEL; CARDIAC STEM CELL; CARDIOTOXICITY; CARDIOVASCULAR SYSTEM; CELL HOMING; CELL MIGRATION; CELL REGENERATION; CELL SELF-RENEWAL; CORONARY ARTERY DISEASE; DENDRITIC CELL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FIBROBLAST; HEART; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MOLECULAR MECHANICS; OXIDATIVE STRESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANGIOGENESIS; ANIMAL; CARDIOVASCULAR DISEASES; DRUG EFFECTS; ENZYMOLOGY; FIBROSIS; GENETICS; HEART MUSCLE; HEART VENTRICLE REMODELING; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; REGENERATION; VASCULAR REMODELING;

ANIMALS; APOPTOSIS; AUTOPHAGY; BLOOD VESSELS; CARDIOVASCULAR DISEASES; DENDRITIC CELLS; FIBROSIS; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; MOLECULAR TARGETED THERAPY; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-MET; REGENERATION; SIGNAL TRANSDUCTION; VASCULAR REMODELING; VENTRICULAR REMODELING;

EID: 84952001288     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20150502     Document Type: Review

References (203)

1. Nakamura, T., Nawa, K. and Ichihara, A. (1984) Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem. Biophys. Res. Commun. 122, 1450-1459
2. Weidner, K.M., Behrens, J., Vandekerckhove, J. and Birchmeier, W. (1990) Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J. Cell Biol. 111, 2097-2108
3. Bottaro, D.P., Rubin, J.S., Faletto, D.L., Chan, A.M., Kmiecik, T.E., Vande Woude, G.F. and Aaronson, S.A. (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802-804
4. Naldini, L., Weidner, K.M., Vigna, E., Gaudino, G., Bardelli, A., Ponzetto, C., Narsimhan, R.P., Hartmann, G., Zarnegar, R., Michalopoulos, G.K. et al. (1991) Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 10, 2867-2878
5. Birchmeier, C., Birchmeier, W., Gherardi, E. and Vande Woude, G.F. (2003) Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4, 915-925
6. Trusolino, L., Bertotti, A. and Comoglio, P.M. (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 11, 834-848
7. Sala, V. and Crepaldi, T. (2011) Novel therapy for myocardial infarction: can HGF/Met be beneficial? Cell. Mol. Life Sci. 68, 1703-1717
8. Gallo, S., Sala, V., Gatti, S. and Crepaldi, T. (2014) HGF/Met axis in heart function and cardioprotection. Biomedicines 2, 247-262
9. Graziani, A., Gramaglia, D., dalla Zonca, P. and Comoglio, P.M. (1993) Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger. J. Biol. Chem. 268, 9165-9168
10. Nakaoka, Y., Nishida, K., Narimatsu, M., Kamiya, A., Minami, T., Sawa, H., Okawa, K., Fujio, Y., Koyama, T., Maeda, M. et al. (2007) Gab family proteins are essential for postnatal maintenance of cardiac function via neuregulin-1/ErbB signaling. J. Clin. Invest. 117, 1771-1781
11. Sala, V., Gallo, S., Leo, C., Gatti, S., Gelb, B.D. and Crepaldi, T. (2012) Signaling to cardiac hypertrophy: insights from human and mouse RASopathies. Mol. Med. 18, 938-947
12. Kerr, B.A., Ma, L., West, X.Z., Ding, L., Malinin, N.L., Weber, M.E., Tischenko, M., Goc, A., Somanath, P.R., Penn, M.S. et al. (2013) Interference with Akt signaling protects against myocardial infarction and death by limiting the consequences of oxidative stress. Sci. Signal. 6, ra67
13. Hashigasako, A., Machide, M., Nakamura, T. and Matsumoto, K. (2004) Bi-directional regulation of Ser-985 phosphorylation of c-met via protein kinase C and protein phosphatase 2A involves c-Met activation and cellular responsiveness to hepatocyte growth factor. J. Biol. Chem. 279, 26445-26452
14. Peschard, P., Fournier, T.M., Lamorte, L., Naujokas, M.A., Band, H., Langdon, W.Y. and Park, M. (2001) Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8, 995-1004
15. Kawaguchi, M. and Kataoka, H. (2014) Mechanisms of hepatocyte growth factor activation in cancer tissues. Cancers (Basel) 6, 1890-1904
16. Rappolee, D.A., Iyer, A. and Patel, Y. (1996) Hepatocyte growth factor and its receptor are expressed in cardiac myocytes during early cardiogenesis. Circ. Res. 78, 1028-1036
17. Song, W., Majka, S.M. and McGuire, P.G. (1999) Hepatocyte growth factor expression in the developing myocardium: evidence for a role in the regulation of the mesenchymal cell phenotype and urokinase expression. Dev. Dyn. 214, 92-100
18. Gatti, S., Leo, C., Gallo, S., Sala, V., Bucci, E., Natale, M., Cantarella, D., Medico, E. and Crepaldi, T. (2013) Gene expression profiling of HGF/Met activation in neonatal mouse heart. Transgenic Res. 22, 579-593
19. Matsumori, A., Furukawa, Y., Hashimoto, T., Ono, K., Shioi, T., Okada, M., Iwasaki, A., Nishio, R. and Sasayama, S. (1996) Increased circulating hepatocyte growth factor in the early stage of acute myocardial infarction. Biochem. Biophys. Res. Commun. 221, 391-395
20. Ono, K., Matsumori, A., Shioi, T., Furukawa, Y. and Sasayama, S. (1997) Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 95, 2552-2558
21. Leo, C., Sala, V., Morello, M., Chiribiri, A., Riess, I., Mancardi, D., Schiaffino, S., Ponzetto, C. and Crepaldi, T. (2011) Activated Met signalling in the developing mouse heart leads to cardiac disease. PLoS One 6, e14675
22. Gallo, S., Gatti, S., Sala, V., Albano, R., Costelli, P., Casanova, E., Comoglio, P.M. and Crepaldi, T. (2014) Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy. Cell Death Dis 5, e1185
23. Liu, Y. (1999) Hepatocyte growth factor promotes renal epithelial cell survival by dual mechanisms. Am. J. Physiol. 277, F624-F633
24. Kitta, K., Day, R.M., Kim, Y., Torregroza, I., Evans, T. and Suzuki, Y.J. (2003) Hepatocyte growth factor induces GATA-4 phosphorylation and cell survival in cardiac muscle cells. J. Biol. Chem. 278, 4705-4712
25. Gude, N.A., Emmanuel, G., Wu, W., Cottage, C.T., Fischer, K., Quijada, P., Muraski, J.A., Alvarez, R., Rubio, M., Schaefer, E. and Sussman, M.A. (2008) Activation of Notch-mediated protective signaling in the myocardium. Circ. Res. 102, 1025-1035
26. de la Pompa, J.L. and Epstein, J.A. (2012) Coordinating tissue interactions: Notch signaling in cardiac development and disease. Dev. Cell 22, 244-254
27. Pattingre, S., Tassa, A., Qu, X., Garuti, R., Liang, X.H., Mizushima, N., Packer, M., Schneider, M.D. and Levine, B. (2005) Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122, 927-939
28. Imazu, T., Shimizu, S., Tagami, S., Matsushima, M., Nakamura, Y., Miki, T., Okuyama, A. and Tsujimoto, Y. (1999) Bcl-2/E1B 19 kDa-interacting protein 3-like protein (Bnip3L) interacts with bcl-2/Bcl-xL and induces apoptosis by altering mitochondrial membrane permeability. Oncogene 18, 4523-4529
29. Arechederra, M., Carmona, R., Gonzalez-Nunez, M., Gutierrez-Uzquiza, A., Bragado, P., Cruz-Gonzalez, I., Cano, E., Guerrero, C., Sanchez, A., Lopez-Novoa, J.M. et al. (2013) Met signaling in cardiomyocytes is required for normal cardiac function in adult mice. Biochim. Biophys. Acta 1832, 2204-2215
30. Gomez-Quiroz, L.E., Factor, V.M., Kaposi-Novak, P., Coulouarn, C., Conner, E.A. and Thorgeirsson, S.S. (2008) Hepatocyte-specific c-Met deletion disrupts redox homeostasis and sensitizes to Fas-mediated apoptosis. J. Biol. Chem. 283, 14581-14589
31. Kaposi-Novak, P., Lee, J.S., Gomez-Quiroz, L., Coulouarn, C., Factor, V.M. and Thorgeirsson, S.S. (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest. 116, 1582-1595
32. Comoglio, P.M., Giordano, S. and Trusolino, L. (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 7, 504-516
33. Doherty, K.R., Wappel, R.L., Talbert, D.R., Trusk, P.B., Moran, D.M., Kramer, J.W., Brown, A.M., Shell, S.A. and Bacus, S. (2013) Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol. Appl. Pharmacol. 272, 245-255
34. Aguirre, S.A., Heyen, J.R., Collette, 3rd, W., Bobrowski, W. and Blasi, E.R. (2010) Cardiovascular effects in rats following exposure to a receptor tyrosine kinase inhibitor. Toxicol. Pathol. 38, 416-428
35. Bussolino, F., Renzo, M.F., Ziche, M., Bocchietto, E., Olivero, M., Naldini, L., Gaudino, G., Tamagnone, L., Coffer, A. and Comoglio, P.M. (1992) Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol. 119, 629-641
36. Grant, D.S., Kleinman, H.K., Goldberg, I.D., Bhargava, M.M., Nickoloff, B.J., Kinsella, J.L., Polverini, P. and Rosen, E.M. (1993) Scatter factor induces blood vessel formation in vivo. Proc. Natl. Acad. Sci. U.S.A. 90, 1937-1941
37. Ding, S., Merkulova-Rainon, T., Han, Z.C. and Tobelem, G. (2003) HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood 101, 4816-4822
38. Nakagami, H., Morishita, R., Yamamoto, K., Taniyama, Y., Aoki, M., Kim, S., Matsumoto, K., Nakamura, T., Higaki, J. and Ogihara, T. (2000) Anti-apoptotic action of hepatocyte growth factor through mitogen-activated protein kinase on human aortic endothelial cells. J. Hypertens. 18, 1411-1420
39. Yamamoto, Y., Kohara, K., Tabara, Y. and Miki, T. (2001) Association between carotid arterial remodeling and plasma concentration of circulating hepatocyte growth factor. J. Hypertens. 19, 1975-1979
40. Nakagami, H., Morishita, R., Yamamoto, K., Taniyama, Y., Aoki, M., Matsumoto, K., Nakamura, T., Kaneda, Y., Horiuchi, M. and Ogihara, T. (2001) Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertension 37, 581-586
41. Belle, E., Witzenbichler, B., Chen, D., Silver, M., Chang, L., Schwall, R. and Isner, J.M. (1998) Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 97, 381-390
42. Rosario, M. and Birchmeier, W. (2003) How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol. 13, 328-335
43. Gerritsen, M.E., Tomlinson, J.E., Zlot, C., Ziman, M. and Hwang, S. (2003) Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br. J. Pharmacol. 140, 595-610
44. Weis, S.M. and Cheresh, D.A. (2005) Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437, 497-504
45. Liu, F., Schaphorst, K.L., Verin, A.D., Jacobs, K., Birukova, A., Day, R.M., Bogatcheva, N., Bottaro, D.P. and Garcia, J.G. (2002) Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase-3β. FASEB J 16, 950-962
46. Singleton, P.A., Salgia, R., Moreno-Vinasco, L., Moitra, J., Sammani, S., Mirzapoiazova, T. and Garcia, J.G. (2007) CD44 regulates hepatocyte growth factor-mediated vascular integrity: role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J. Biol. Chem. 282, 30643-30657
47. Birukova, A.A., Cokic, I., Moldobaeva, N. and Birukov, K.G. (2009) Paxillin is involved in the differential regulation of endothelial barrier by HGF and VEGF. Am. J. Respir. Cell Mol. Biol. 40, 99-107
48. Meng, F., Meliton, A., Moldobaeva, N., Mutlu, G., Kawasaki, Y., Akiyama, T. and Birukova, A.A. (2015) Asef mediates HGF protective effects against LPS-induced lung injury and endothelial barrier dysfunction. Am. J. Physiol. Lung Cell. Mol. Physiol. 308, L452-L463
49. Tian, Y., Gawlak, G., Shah, A.S., Higginbotham, K., Tian, X., Kawasaki, Y., Akiyama, T., Sacks, D.B. and Birukova, A.A. (2015) Hepatocyte growth factor-induced Asef-IQGAP1 complex controls cytoskeletal remodeling and endothelial barrier. J. Biol. Chem. 290, 4097-4109
50. Tian, Y., Tian, X., Gawlak, G., O'Donnell, 3rd, J.J., Sacks, D.B. and Birukova, A.A. (2014) IQGAP1 regulates endothelial barrier function via EB1-cortactin cross talk. Mol. Cell. Biol. 34, 3546-3558
51. Sulpice, E., Ding, S., Muscatelli-Groux, B., Berge, M., Han, Z.C., Plouet, J., Tobelem, G. and Merkulova-Rainon, T. (2009) Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells. Biol. Cell 101, 525-539
52. Sulpice, E., Plouet, J., Berge, M., Allanic, D., Tobelem, G. and Merkulova-Rainon, T. (2008) Neuropilin-1 and neuropilin-2 act as coreceptors, potentiating proangiogenic activity. Blood 111, 2036-2045
53. Sanada, F., Taniyama, Y., Azuma, J., Iekushi, K., Dosaka, N., Yokoi, T., Koibuchi, N., Kusunoki, H., Aizawa, Y. and Morishita, R. (2009) Hepatocyte growth factor, but not vascular endothelial growth factor, attenuates angiotensin II-induced endothelial progenitor cell senescence. Hypertension 53, 77-82
54. Wang, Y., Ahmad, N., Wani, M.A. and Ashraf, M. (2004) Hepatocyte growth factor prevents ventricular remodeling and dysfunction in mice via Akt pathway and angiogenesis. J. Mol. Cell. Cardiol. 37, 1041-1052
55. Aoki, M., Morishita, R., Taniyama, Y., Kida, I., Moriguchi, A., Matsumoto, K., Nakamura, T., Kaneda, Y., Higaki, J. and Ogihara, T. (2000) Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther. 7, 417-427
56. Riess, I., Sala, V., Leo, C., Demaria, M., Gatti, S., Gallo, S., Fitou, A., Boero, O., Levi, R., Cuccovillo, I. et al. (2011) A mouse model for spatial and temporal expression of HGF in the heart. Transgenic Res. 20, 1203-1216
57. Morishita, R., Nakamura, S., Hayashi, S., Taniyama, Y., Moriguchi, A., Nagano, T., Taiji, M., Noguchi, H., Takeshita, S., Matsumoto, K. et al. (1999) Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 33, 1379-1384
58. Hayashi, S., Morishita, R., Nakamura, S., Yamamoto, K., Moriguchi, A., Nagano, T., Taiji, M., Noguchi, H., Matsumoto, K., Nakamura, T. et al. (1999) Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells. Circulation 100 Suppl., II301-II308
59. Kobayashi, H., DeBusk, L.M., Babichev, Y.O., Dumont, D.J. and Lin, P.C. (2006) Hepatocyte growth factor mediates angiopoietin-induced smooth muscle cell recruitment. Blood 108, 1260-1266
60. Shimizu, K., Taniyama, Y., Sanada, F., Azuma, J., Iwabayashi, M., Iekushi, K., Rakugi, H. and Morishita, R. (2012) Hepatocyte growth factor inhibits lipopolysaccharide-induced oxidative stress via epithelial growth factor receptor degradation. Arterioscler. Thromb. Vasc. Biol. 32, 2687-2693
61. Matsumoto, K., Morishita, R., Tomita, N., Moriguchi, A., Yamasaki, K., Aoki, M., Nakamura, T., Higaki, J. and Ogihara, T. (2002) Impaired endothelial dysfunction in diabetes mellitus rats was restored by oral administration of prostaglandin I2 analogue. J. Endocrinol. 175, 217-223
62. Matsumoto, K., Morishita, R., Tomita, N., Moriguchi, A., Komai, N., Aoki, M., Nakamura, T., Higaki, J. and Ogihara, T. (2003) Improvement of endothelial dysfunction by angiotensin II blockade accompanied by induction of vascular hepatocyte growth factor system in diabetic spontaneously hypertensive rats. Heart Vessels 18, 18-25
63. Dzau, V.J. (1993) The role of mechanical and humoral factors in growth regulation of vascular smooth muscle and cardiac myocytes. Curr. Opin. Nephrol. Hypertens. 2, 27-32
64. Taher, T.E., Derksen, P.W., de Boer, O.J., Spaargaren, M., Teeling, P., van der Wal, A.C. and Pals, S.T. (2002) Hepatocyte growth factor triggers signaling cascades mediating vascular smooth muscle cell migration. Biochem. Biophys. Res. Commun. 298, 80-86
65. McKinnon, H., Gherardi, E., Reidy, M. and Bowyer, D. (2006) Hepatocyte growth factor/scatter factor and MET are involved in arterial repair and atherogenesis. Am. J. Pathol. 168, 340-348
66. Liu, Y., Wang, T., Yan, J., Jiagbogu, N., Heideman, D.A., Canfield, A.E. and Alexander, M.Y. (2011) HGF/c-Met signalling promotes Notch3 activation and human vascular smooth muscle cell osteogenic differentiation in vitro. Atherosclerosis 219, 440-447
67. Campbell, S.E. and Katwa, L.C. (1997) Angiotensin II stimulated expression of transforming growth factor-β1 in cardiac fibroblasts and myofibroblasts. J. Mol. Cell. Cardiol. 29, 1947-1958
68. Lee, A.A., Dillmann, W.H., McCulloch, A.D. and Villarreal, F.J. (1995) Angiotensin II stimulates the autocrine production of transforming growth factor-β1 in adult rat cardiac fibroblasts. J. Mol. Cell. Cardiol. 27, 2347-2357
69. MacKenna, D., Summerour, S.R. and Villarreal, F.J. (2000) Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc. Res. 46, 257-263
70. Kim, N.N., Villarreal, F.J., Printz, M.P., Lee, A.A. and Dillmann, W.H. (1995) Trophic effects of angiotensin II on neonatal rat cardiac myocytes are mediated by cardiac fibroblasts. Am. J. Physiol. 269, E426-E437
71. Nakamura, T., Matsumoto, K., Mizuno, S., Sawa, Y. and Matsuda, H. (2005) Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts. Am. J. Physiol. Heart Circ. Physiol. 288, H2131-H2139
72. Taniyama, Y., Morishita, R., Nakagami, H., Moriguchi, A., Sakonjo, H., Shokei, K., Matsumoto, K., Nakamura, T., Higaki, J. and Ogihara, T. (2000) Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 102, 246-252
73. Ueki, T., Kaneda, Y., Tsutsui, H., Nakanishi, K., Sawa, Y., Morishita, R., Matsumoto, K., Nakamura, T., Takahashi, H., Okamoto, E. and Fujimoto, J. (1999) Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat. Med. 5, 226-230
74. Kobayashi, E., Sasamura, H., Mifune, M., Shimizu-Hirota, R., Kuroda, M., Hayashi, M. and Saruta, T. (2003) Hepatocyte growth factor regulates proteoglycan synthesis in interstitial fibroblasts. Kidney Int. 64, 1179-1188
75. Mizuno, S., Matsumoto, K., Li, M.Y. and Nakamura, T. (2005) HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J. 19, 580-582
76. Azuma, J., Taniyama, Y., Takeya, Y., Iekushi, K., Aoki, M., Dosaka, N., Matsumoto, K., Nakamura, T., Ogihara, T. and Morishita, R. (2006) Angiogenic and antifibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy. Gene Ther. 13, 1206-1213
77. Jayasankar, V., Woo, Y.J., Bish, L.T., Pirolli, T.J., Chatterjee, S., Berry, M.F., Burdick, J., Gardner, T.J. and Sweeney, H.L. (2003) Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure. Circulation 108 (Suppl. 1), II230-II236
78. Chen, X.H., Minatoguchi, S., Kosai, K., Yuge, K., Takahashi, T., Arai, M., Wang, N., Misao, Y., Lu, C., Onogi, H. et al. (2007) In vivo hepatocyte growth factor gene transfer reduces myocardial ischemia-reperfusion injury through its multiple actions. J. Card. Fail. 13, 874-883
79. Taniyama, Y., Morishita, R., Aoki, M., Hiraoka, K., Yamasaki, K., Hashiya, N., Matsumoto, K., Nakamura, T., Kaneda, Y. and Ogihara, T. (2002) Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension 40, 47-53
80. Marquardt, J.U., Seo, D., Gomez-Quiroz, L.E., Uchida, K., Gillen, M.C., Kitade, M., Kaposi-Novak, P., Conner, E.A., Factor, V.M. and Thorgeirsson, S.S. (2012) Loss of c-Met accelerates development of liver fibrosis in response to CCl4 exposure through deregulation of multiple molecular pathways. Biochim. Biophys. Acta 1822, 942-951
81. Okayama, K., Azuma, J., Dosaka, N., Iekushi, K., Sanada, F., Kusunoki, H., Iwabayashi, M., Rakugi, H., Taniyama, Y. and Morishita, R. (2012) Hepatocyte growth factor reduces cardiac fibrosis by inhibiting endothelial-mesenchymal transition. Hypertension 59, 958-965
82. Purdie, K.J., Whitley, G.S., Johnstone, A.P. and Cartwright, J.E. (2002) Hepatocyte growth factor-induced endothelial cell motility is mediated by the upregulation of inducible nitric oxide synthase expression. Cardiovasc. Res. 54, 659-668
83. Takemoto, M., Egashira, K., Tomita, H., Usui, M., Okamoto, H., Kitabatake, A., Shimokawa, H., Sueishi, K. and Takeshita, A. (1997) Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 30, 1621-1627
84. Tomita, H., Egashira, K., Ohara, Y., Takemoto, M., Koyanagi, M., Katoh, M., Yamamoto, H., Tamaki, K., Shimokawa, H. and Takeshita, A. (1998) Early induction of transforming growth factor-β via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 32, 273-279
85. Nishino, T., Hisha, H., Nishino, N., Adachi, M. and Ikehara, S. (1995) Hepatocyte growth factor as a hematopoietic regulator. Blood 85, 3093-3100
86. Molnarfi, N., Benkhoucha, M., Funakoshi, H., Nakamura, T. and Lalive, P.H. (2015) Hepatocyte growth factor: a regulator of inflammation and autoimmunity. Autoimmun. Rev. 14, 293-303
87. Galimi, F., Cottone, E., Vigna, E., Arena, N., Boccaccio, C., Giordano, S., Naldini, L. and Comoglio, P.M. (2001) Hepatocyte growth factor is a regulator of monocyte-macrophage function. J. Immunol. 166, 1241-1247
88. Moransard, M., Sawitzky, M., Fontana, A. and Suter, T. (2010) Expression of the HGF receptor c-met by macrophages in experimental autoimmune encephalomyelitis. Glia 58, 559-571
89. + regulatory T cells. Proc. Natl. Acad. Sci. U.S.A. 107, 6424-6429
90. Okunishi, K., Dohi, M., Nakagome, K., Tanaka, R., Mizuno, S., Matsumoto, K., Miyazaki, J., Nakamura, T. and Yamamoto, K. (2005) A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. J. Immunol. 175, 4745-4753
91. Kurz, S.M., Diebold, S.S., Hieronymus, T., Gust, T.C., Bartunek, P., Sachs, M., Birchmeier, W. and Zenke, M. (2002) The impact of c-met/scatter factor receptor on dendritic cell migration. Eur. J. Immunol. 32, 1832-1838
92. Finisguerra, V., Conza, G., Matteo, M., Serneels, J., Costa, S., Thompson, A.A., Wauters, E., Walmsley, S., Prenen, H., Granot, Z. et al. (2015) MET is required for the recruitment of anti-tumoural neutrophils. Nature 522, 349-353
93. Beilmann, M., Odenthal, M., Jung, W., Woude, G.F., Dienes, H.P. and Schirmacher, P. (1997) Neoexpression of the c-met/hepatocyte growth factor-scatter factor receptor gene in activated monocytes. Blood 90, 4450-4458
94. Beilmann, M., Woude, G.F., Dienes, H.P. and Schirmacher, P. (2000) Hepatocyte growth factor-stimulated invasiveness of monocytes. Blood 95, 3964-3969
95. low/neg accessory cells with dendritic-cell features. Blood 108, 218-227
96. Coudriet, G.M., He, J., Trucco, M., Mars, W.M. and Piganelli, J.D. (2010) Hepatocyte growth factor modulates interleukin-6 production in bone marrow derived macrophages: implications for inflammatory mediated diseases. PLoS One 5, e15384
97. Yang, Z., Zingarelli, B. and Szabo, C. (2000) Crucial role of endogenous interleukin-10 production in myocardial ischemia/reperfusion injury. Circulation 101, 1019-1026
98. Yang, Z.J., Xu, S.L., Chen, B., Zhang, S.L., Zhang, Y.L., Wei, W., Ma, D.C., Wang, L.S., Zhu, T.B., Li, C.J. et al. (2009) Hepatocyte growth factor plays a critical role in the regulation of cytokine production and induction of endothelial progenitor cell mobilization: a pilot gene therapy study in patients with coronary heart disease. Clin. Exp. Pharmacol. Physiol. 36, 790-796
99. Mallat, Z., Besnard, S., Duriez, M., Deleuze, V., Emmanuel, F., Bureau, M.F., Soubrier, F., Esposito, B., Duez, H., Fievet, C. et al. (1999) Protective role of interleukin-10 in atherosclerosis. Circ. Res. 85, e17-e24
100. Mostafa Mtairag, E., Chollet-Martin, S., Oudghiri, M., Laquay, N., Jacob, M.P., Michel, J.B. and Feldman, L.J. (2001) Effects of interleukin-10 on monocyte/endothelial cell adhesion and MMP-9/TIMP-1 secretion. Cardiovasc. Res. 49, 882-890
101. Smith, D.A., Irving, S.D., Sheldon, J., Cole, D. and Kaski, J.C. (2001) Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 104, 746-749
102. Yue, T.L., Wang, X., Sung, C.P., Olson, B., McKenna, P.J., Gu, J.L. and Feuerstein, G.Z. (1994) Interleukin-8: a mitogen and chemoattractant for vascular smooth muscle cells. Circ. Res. 75, 1-7
103. Gerszten, R.E., Garcia-Zepeda, E.A., Lim, Y.C., Yoshida, M., Ding, H.A., Jr, M.A., Luster, A.D., Luscinskas, F.W. and Rosenzweig, A. (1999) MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398, 718-723
104. Molad, Y., Haines, K.A., Anderson, D.C., Buyon, J.P. and Cronstein, B.N. (1994) Immunocomplexes stimulate different signalling events to chemoattractants in the neutrophil and regulate L-selectin and β2-integrin expression differently. Biochem J. 299, 881-887
105. Peveri, P., Walz, A., Dewald, B. and Baggiolini, M. (1988) A novel neutrophil-activating factor produced by human mononuclear phagocytes. J. Exp. Med. 167, 1547-1559
106. Shintani, Y., Aoki, H., Nishihara, M., Ohno, S., Furusho, A., Hiromatsu, S., Akashi, H., Imaizumi, T. and Aoyagi, S. (2011) Hepatocyte growth factor promotes an anti-inflammatory cytokine profile in human abdominal aortic aneurysm tissue. Atherosclerosis 216, 307-312
107. Sakaguchi, S., Shono, J., Suzuki, T., Sawano, S., Anderson, J.E., Do, M.K., Ohtsubo, H., Mizunoya, W., Sato, Y., Nakamura, M. et al. (2014) Implication of anti-inflammatory macrophages in regenerative moto-neuritogenesis: promotion of myoblast migration and neural chemorepellent semaphorin 3A expression in injured muscle. Int. J. Biochem. Cell Biol. 54, 272-285
108. Dutta, P. and Nahrendorf, M. (2015) Monocytes in myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 35, 1066-1070
109. De Palma, M., Venneri, M.A., Galli, R., Sergi Sergi, L., Politi, L.S., Sampaolesi, M. and Naldini, L. (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8, 211-226
110. Futamatsu, H., Suzuki, J., Mizuno, S., Koga, N., Adachi, S., Kosuge, H., Maejima, Y., Hirao, K., Nakamura, T. and Isobe, M. (2005) Hepatocyte growth factor ameliorates the progression of experimental autoimmune myocarditis: a potential role for induction of T helper 2 cytokines. Circ. Res. 96, 823-830
111. Yamaura, K., Ito, K., Tsukioka, K., Wada, Y., Makiuchi, A., Sakaguchi, M., Akashima, T., Fujimori, M., Sawa, Y., Morishita, R. et al. (2004) Suppression of acute and chronic rejection by hepatocyte growth factor in a murine model of cardiac transplantation: induction of tolerance and prevention of cardiac allograft vasculopathy. Circulation 110, 1650-1657
112. Bai, L., Lennon, D.P., Caplan, A.I., DeChant, A., Hecker, J., Kranso, J., Zaremba, A. and Miller, R.H. (2012) Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat. Neurosci. 15, 862-870
113. Dallman, M.J., Larsen, C.P. and Morris, P.J. (1991) Cytokine gene transcription in vascularised organ grafts: analysis using semiquantitative polymerase chain reaction. J. Exp. Med. 174, 493-496
114. Saiura, A., Mataki, C., Murakami, T., Umetani, M., Wada, Y., Kohro, T., Aburatani, H., Harihara, Y., Hamakubo, T., Yamaguchi, T. et al. (2001) A comparison of gene expression in murine cardiac allografts and isografts by means DNA microarray analysis. Transplantation 72, 320-329
115. Nagano, H., Mitchell, R.N., Taylor, M.K., Hasegawa, S., Tilney, N.L. and Libby, P. (1997) Interferon-γ deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J. Clin. Invest. 100, 550-557
116. Mirotsou, M., Jayawardena, T.M., Schmeckpeper, J., Gnecchi, M. and Dzau, V.J. (2011) Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J. Mol. Cell. Cardiol. 50, 280-289
117. Chimenti, I., Smith, R.R., Li, T.S., Gerstenblith, G., Messina, E., Giacomello, A. and Marban, E. (2010) Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ. Res. 106, 971-980
118. Malliaras, K., Zhang, Y., Seinfeld, J., Galang, G., Tseliou, E., Cheng, K., Sun, B., Aminzadeh, M. and Marban, E. (2013) Cardiomyocyte proliferation and progenitor cell recruitment underlie therapeutic regeneration after myocardial infarction in the adult mouse heart. EMBO Mol. Med. 5, 191-209
119. Neuss, S., Becher, E., Woltje, M., Tietze, L. and Jahnen-Dechent, W. (2004) Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells 22, 405-414
120. Rosova, I., Dao, M., Capoccia, B., Link, D. and Nolta, J.A. (2008) Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 26, 2173-2182
121. Urbanek, K., Rota, M., Cascapera, S., Bearzi, C., Nascimbene, A., De Angelis, A., Hosoda, T., Chimenti, S., Baker, M., Limana, F. et al. (2005) Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ. Res. 97, 663-673
122. Rehman, J., Li, J., Orschell, C.M. and March, K.L. (2003) Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107, 1164-1169
123. Cho, H.J., Lee, N., Lee, J.Y., Choi, Y.J., Ii, M., Wecker, A., Jeong, J.O., Curry, C., Qin, G. and Yoon, Y.S. (2007) Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart. J. Exp. Med. 204, 3257-3269
124. Urbich, C., Aicher, A., Heeschen, C., Dernbach, E., Hofmann, W.K., Zeiher, A.M. and Dimmeler, S. (2005) Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J. Mol. Cell. Cardiol. 39, 733-742
125. Cai, L., Johnstone, B.H., Cook, T.G., Liang, Z., Traktuev, D., Cornetta, K., Ingram, D.A., Rosen, E.D. and March, K.L. (2007) Suppression of hepatocyte growth factor production impairs the ability of adipose-derived stem cells to promote ischemic tissue revascularization. Stem Cells 25, 3234-3243
126. Ellison, G.M., Torella, D., Dellegrottaglie, S., Perez-Martinez, C., Perez de Prado, A., Vicinanza, C., Purushothaman, S., Galuppo, V., Iaconetti, C., Waring, C.D. et al. (2011) Endogenous cardiac stem cell activation by insulin-like growth factor-1/hepatocyte growth factor intracoronary injection fosters survival and regeneration of the infarcted pig heart. J. Am. Coll. Cardiol. 58, 977-986
127. Koudstaal, S., Bastings, M.M., Feyen, D.A., Waring, C.D., van Slochteren, F.J., Dankers, P.Y., Torella, D., Sluijter, J.P., Nadal-Ginard, B., Doevendans, P.A. et al. (2014) Sustained delivery of insulin-like growth factor-1/hepatocyte growth factor stimulates endogenous cardiac repair in the chronic infarcted pig heart. J. Cardiovasc. Transl. Res. 7, 232-241
128. Torella, D., Ellison, G.M., Mendez-Ferrer, S., Ibanez, B. and Nadal-Ginard, B. (2006) Resident human cardiac stem cells: role in cardiac cellular homeostasis and potential for myocardial regeneration. Nat. Clin. Pract. Cardiovasc. Med. 3 Suppl. 1, S8-S13
129. Barile, L., Messina, E., Giacomello, A. and Marbán, E. (2007) Endogenous cardiac stem cells. Prog. Cardiovasc. Dis. 50, 31-48
130. Leri, A., Rota, M., Pasqualini, F.S., Goichberg, P. and Anversa, P. (2015) Origin of cardiomyocytes in the adult heart. Circ. Res. 116, 150-166
131. Parmacek, M.S. and Epstein, J.A. (2005) Pursuing cardiac progenitors: regeneration redux. Cell 120, 295-298
132. Leri, A., Kajstura, J. and Anversa, P. (2005) Cardiac stem cells and mechanisms of myocardial regeneration. Physiol. Rev. 85, 1373-1416
133. Smith, R.R., Barile, L., Cho, H.C., Leppo, M.K., Hare, J.M., Messina, E., Giacomello, A., Abraham, M.R. and Marban, E. (2007) Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 115, 896-908
134. Leri, A., Rota, M., Hosoda, T., Goichberg, P. and Anversa, P. (2014) Cardiac stem cell niches. Stem Cell Res. 13, 631-646
135. Pagliari, S., Jelinek, J., Grassi, G. and Forte, G. (2014) Targeting pleiotropic signaling pathways to control adult cardiac stem cell fate and function. Front. Physiol. 5, 219
136. Boni, A., Urbanek, K., Nascimbene, A., Hosoda, T., Zheng, H., Delucchi, F., Amano, K., Gonzalez, A., Vitale, S., Ojaimi, C. et al. (2008) Notch1 regulates the fate of cardiac progenitor cells. Proc. Natl. Acad. Sci. U.S.A. 105, 15529-15534
137. Ishikawa, T., Factor, V.M., Marquardt, J.U., Raggi, C., Seo, D., Kitade, M., Conner, E.A. and Thorgeirsson, S.S. (2012) Hepatocyte growth factor/c-met signaling is required for stem-cell-mediated liver regeneration in mice. Hepatology 55, 1215-1226
138. Chmielowiec, J., Borowiak, M., Morkel, M., Stradal, T., Munz, B., Werner, S., Wehland, J., Birchmeier, C. and Birchmeier, W. (2007) c-Met is essential for wound healing in the skin. J. Cell Biol. 177, 151-162
139. Webster, M.T. and Fan, C.M. (2013) c-MET regulates myoblast motility and myocyte fusion during adult skeletal muscle regeneration. PLoS One 8, e81757
140. Li, Y., Li, A., Glas, M., Lal, B., Ying, M., Sang, Y., Xia, S., Trageser, D., Guerrero-Cázares, H., Eberhart, C.G. et al. (2011) c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc. Natl. Acad. Sci. U.S.A. 108, 9951-9956
141. De Bacco, F., Casanova, E., Medico, E., Pellegatta, S., Orzan, F., Albano, R., Luraghi, P., Reato, G., D'Ambrosio, A., Porrati, P. et al. (2012) The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res. 72, 4537-4550
142. Xu, K., Usary, J., Kousis, P.C., Prat, A., Wang, D.Y., Adams, J.R., Wang, W., Loch, A.J., Deng, T., Zhao, W. et al. (2012) Lunatic fringe deficiency cooperates with the Met/caveolin gene amplicon to induce basal-like breast cancer. Cancer Cell 21, 626-641
143. Gastaldi, S., Sassi, F., Accornero, P., Torti, D., Galimi, F., Migliardi, G., Molyneux, G., Perera, T., Comoglio, P.M., Boccaccio, C. et al. (2013) Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. Oncogene 32, 1428-1440
144. Smart, N., Bollini, S., Dube, K.N., Vieira, J.M., Zhou, B., Davidson, S., Yellon, D., Riegler, J., Price, A.N., Lythgoe, M.F. et al. (2011) De novo cardiomyocytes from within the activated adult heart after injury. Nature 474, 640-644
145. + cells: role of the pericardial fluid. J. Mol. Cell. Cardiol. 48, 609-618
146. Rao, K.S., Aronshtam, A., McElory-Yaggy, K.L., Bakondi, B., VanBuren, P., Sobel, B.E. and Spees, J.L. (2015) Human epicardial cell-conditioned medium contains HGF/IgG complexes that phosphorylate RYK and protect against vascular injury. Cardiovasc. Res. 107, 277-286
147. Rennert, R.C., Sorkin, M., Garg, R.K. and Gurtner, G.C. (2012) Stem cell recruitment after injury: lessons for regenerative medicine. Regen. Med. 7, 833-850
148. Kucia, M., Dawn, B., Hunt, G., Guo, Y., Wysoczynski, M., Majka, M., Ratajczak, J., Rezzoug, F., Ildstad, S.T., Bolli, R. and Ratajczak, M.Z. (2004) Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction. Circ. Res. 95, 1191-1199
149. Son, B.R., Marquez-Curtis, L.A., Kucia, M., Wysoczynski, M., Turner, A.R., Ratajczak, J., Ratajczak, M.Z. and Janowska-Wieczorek, A. (2006) Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 24, 1254-1264
150. Boccaccio, C. and Comoglio, P.M. (2014) MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure. Curr. Opin. Cell Biol. 31, 98-105
151. Boccaccio, C. and Comoglio, P.M. (2006) Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat. Rev. Cancer 6, 637-645
152. Cohen, M.E., Fainstein, N., Lavon, I. and Ben-Hur, T. (2014) Signaling through three chemokine receptors triggers the migration of transplanted neural precursor cells in a model of multiple sclerosis. Stem Cell Res 13, 227-239
153. Konoplyannikov, M., Haider, K.H., Lai, V.K., Ahmed, R.P., Jiang, S. and Ashraf, M. (2013) Activation of diverse signaling pathways by ex-vivo delivery of multiple cytokines for myocardial repair. Stem Cells Dev. 22, 204-215
154. Todaro, M., Gaggianesi, M., Catalano, V., Benfante, A., Iovino, F., Biffoni, M., Apuzzo, T., Sperduti, I., Volpe, S., Cocorullo, G. et al. (2014) CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14, 342-356
155. Holland, J.D., Gyorffy, B., Vogel, R., Eckert, K., Valenti, G., Fang, L., Lohneis, P., Elezkurtaj, S., Ziebold, U. and Birchmeier, W. (2013) Combined Wnt/β-catenin, Met, and CXCL12/CXCR4 signals characterize basal breast cancer and predict disease outcome. Cell Rep. 5, 1214-1227
156. Miekus, K., Lukasiewicz, E., Jarocha, D., Sekula, M., Drabik, G. and Majka, M. (2013) The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation. Cell Death Dis. 4, e459
157. Komarowska, I., Coe, D., Wang, G., Haas, R., Mauro, C., Kishore, M., Cooper, D., Nadkarni, S., Fu, H., Steinbruchel, D.A. et al. (2015) Hepatocyte growth factor receptor c-Met instructs T cell cardiotropism and promotes T cell migration to the heart via autocrine chemokine release. Immunity 42, 1087-1099
158. Sakaguchi, G., Tambara, K., Sakakibara, Y., Ozeki, M., Yamamoto, M., Premaratne, G., Lin, X., Hasegawa, K., Tabata, Y., Nishimura, K. and Komeda, M. (2005) Control-released hepatocyte growth factor prevents the progression of heart failure in stroke-prone spontaneously hypertensive rats. Ann. Thorac. Surg. 79, 1627-1634
159. Sonnenberg, S.B., Rane, A.A., Liu, C.J., Rao, N., Agmon, G., Suarez, S., Wang, R., Munoz, A., Bajaj, V., Zhang, S. et al. (2015) Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction. Biomaterials 45, 56-63
160. Salimath, A.S., Phelps, E.A., Boopathy, A.V., Che, P.L., Brown, M., Garcia, A.J. and Davis, M.E. (2012) Dual delivery of hepatocyte and vascular endothelial growth factors via a protease-degradable hydrogel improves cardiac function in rats. PLoS One 7, e50980
161. Nakano, J., Marui, A., Muranaka, H., Masumoto, H., Noma, H., Tabata, Y., Ido, A., Tsubouchi, H., Ikeda, T. and Sakata, R. (2014) Effects of hepatocyte growth factor in myocarditis rats induced by immunization with porcine cardiac myosin. Interact. Cardiovasc. Thorac. Surg. 18, 300-307
162. Ruvinov, E., Leor, J. and Cohen, S. (2010) The effects of controlled HGF delivery from an affinity-binding alginate biomaterial on angiogenesis and blood perfusion in a hindlimb ischemia model. Biomaterials 31, 4573-4582
163. Funatsu, T., Sawa, Y., Ohtake, S., Takahashi, T., Matsumiya, G., Matsuura, N., Nakamura, T. and Matsuda, H. (2002) Therapeutic angiogenesis in the ischemic canine heart induced by myocardial injection of naked complementary DNA plasmid encoding hepatocyte growth factor. J. Thorac. Cardiovasc. Surg. 124, 1099-1105
164. Ahmet, I., Sawa, Y., Yamaguchi, T. and Matsuda, H. (2003) Gene transfer of hepatocyte growth factor improves angiogenesis and function of chronic ischemic myocardium in canine heart. Ann. Thorac. Surg. 75, 1283-1287
165. Wang, W., Yang, Z.J., Ma, D.C., Wang, L.S., Xu, S.L., Zhang, Y.R., Cao, K.J., Zhang, F.M. and Ma, W.Z. (2006) Induction of collateral artery growth and improvement of post-infarct heart function by hepatocyte growth factor gene transfer. Acta Pharmacol. Sin. 27, 555-560
166. Jin, Y.N., Inubushi, M., Masamoto, K., Odaka, K., Aoki, I., Tsuji, A.B., Sagara, M., Koizumi, M. and Saga, T. (2012) Long-term effects of hepatocyte growth factor gene therapy in rat myocardial infarct model. Gene Ther. 19, 836-843
167. Li, Y., Takemura, G., Kosai, K., Yuge, K., Nagano, S., Esaki, M., Goto, K., Takahashi, T., Hayakawa, K., Koda, M. et al. (2003) Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. Circulation 107, 2499-2506
168. Ahmet, I., Sawa, Y., Iwata, K. and Matsuda, H. (2002) Gene transfection of hepatocyte growth factor attenuates cardiac remodeling in the canine heart: a novel gene therapy for cardiomyopathy. J. Thorac. Cardiovasc. Surg. 124, 957-963
169. Taniyama, Y., Morishita, R., Hiraoka, K., Aoki, M., Nakagami, H., Yamasaki, K., Matsumoto, K., Nakamura, T., Kaneda, Y. and Ogihara, T. (2001) Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation 104, 2344-2350
170. Morishita, R., Makino, H., Aoki, M., Hashiya, N., Yamasaki, K., Azuma, J., Taniyama, Y., Sawa, Y., Kaneda, Y. and Ogihara, T. (2011) Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler. Thromb. Vasc. Biol. 31, 713-720
171. Makino, H., Aoki, M., Hashiya, N., Yamasaki, K., Azuma, J., Sawa, Y., Kaneda, Y., Ogihara, T. and Morishita, R. (2012) Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease. Arterioscler. Thromb. Vasc. Biol. 32, 2503-2509
172. Yuan, B., Zhao, Z., Zhang, Y.R., Wu, C.T., Jin, W.G., Zhao, S., Wangl, W., Zhang, Y.Y., Zhu, X.L., Wang, L.S. and Huang, J. (2008) Short-term safety and curative effect of recombinant adenovirus carrying hepatocyte growth factor gene on ischemic cardiac disease. In Vivo 22, 629-632
173. Yang, Z.J., Zhang, Y.R., Chen, B., Zhang, S.L., Jia, E.Z., Wang, L.S., Zhu, T.B., Li, C.J., Wang, H., Huang, J. et al. (2009) Phase I clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease. Mol. Biol. Rep. 36, 1323-1329
174. Lu, F., Zhao, X., Wu, J., Cui, Y., Mao, Y., Chen, K., Yuan, Y., Gong, D., Xu, Z. and Huang, S. (2013) MSCs transfected with hepatocyte growth factor or vascular endothelial growth factor improve cardiac function in the infarcted porcine heart by increasing angiogenesis and reducing fibrosis. Int. J. Cardiol. 167, 2524-2532
175. Wang, S., Qin, X., Sun, D., Wang, Y., Xie, X., Fan, W., Liang, D., Pei, X. and Cao, F. (2012) Effects of hepatocyte growth factor overexpressed bone marrow-derived mesenchymal stem cells on prevention from left ventricular remodelling and functional improvement in infarcted rat hearts. Cell Biochem. Funct. 30, 574-581
176. Zhang, J., Wang, L.L., Du, W., Yu, Y.C., Ju, W.Z., Man, Y.L., Li, X.R., Chen, Y., Wang, Z.D., Gu, W.J. et al. (2014) Hepatocyte growth factor modification enhances the anti-arrhythmic properties of human bone marrow-derived mesenchymal stem cells. PLoS One 9, e111246
177. Li, N., Pasha, Z. and Ashraf, M. (2014) Reversal of ischemic cardiomyopathy with Sca-1+ stem cells modified with multiple growth factors. PLoS One 9, e93645
178. Chaparro, R.E., Izutsu, M., Sasaki, T., Sheng, H., Zheng, Y., Sadeghian, H., Qin, T., von Bornstadt, D., Herisson, F., Duan, B. et al. (2015) Sustained functional improvement by hepatocyte growth factor-like small molecule BB3 after focal cerebral ischemia in rats and mice. J. Cereb. Blood Flow Metab. 35, 1044-1053
179. Benoist, C.C., Kawas, L.H., Zhu, M., Tyson, K.A., Stillmaker, L., Appleyard, S.M., Wright, J.W., Wayman, G.A. and Harding, J.W. (2014) The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. J. Pharmacol. Exp. Ther. 351, 390-402
180. Prat, M., Crepaldi, T., Pennacchietti, S., Bussolino, F. and Comoglio, P.M. (1998) Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J. Cell Sci. 111, 237-247
181. Lamblin, N., Susen, S., Dagorn, J., Mouquet, F., Jude, B., Belle, E., Bauters, C. and de Groote, P. (2005) Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure. Am. Heart J. 150, 137-143
182. Kamppa, N., Makela, K.M., Lyytikainen, L.P., Peltonen, N., Hautamaki, J., Seppala, I., Mononen, N., Goebeler, S., Karhunen, P.J., Hervonen, A. et al. (2013) Vascular cell adhesion molecule 1, soluble Fas and hepatocyte growth factor as predictors of mortality in nonagenarians: the Vitality 90+ study. Exp. Gerontol. 48, 1167-1172
183. Morishita, R., Moriguchi, A., Higaki, J. and Ogihara, T. (1999) Hepatocyte growth factor (HGF) as a potential index of severity of hypertension. Hypertens. Res. 22, 161-167
184. Nakamura, S., Morishita, R., Moriguchi, A., Yo, Y., Nakamura, Y., Hayashi, S., Matsumoto, K., Nakamura, T., Higaki, J. and Ogihara, T. (1998) Hepatocyte growth factor as a potential index of complication in diabetes mellitus. J. Hypertens. 16, 2019-2026
185. Ueno, S., Ikeda, U., Hojo, Y., Arakawa, H., Nonaka, M., Yamamoto, K. and Shimada, K. (2001) Serum hepatocyte growth factor levels are increased in patients with congestive heart failure. J. Card. Fail. 7, 329-334
186. Rychli, K., Richter, B., Hohensinner, P.J., Mahdy, A., Neuhold, S., Zorn, G., Berger, R., Mortl, D., Huber, K. et al. (2011) Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure. Heart 97, 1158-1163
187. Richter, B., Koller, L., Hohensinner, P.J., Zorn, G., Brekalo, M., Berger, R., Mortl, D., Maurer, G., Pacher, R., Huber, K. et al. (2013) A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. Int. J. Cardiol. 168, 1251-1257
188. Nakamura, S., Moriguchi, A., Morishita, R., Aoki, M., Yo, Y., Hayashi, S., Nakano, N., Katsuya, T., Nakata, S., Takami, S. et al. (1998) A novel vascular modulator, hepatocyte growth factor (HGF), as a potential index of the severity of hypertension. Biochem. Biophys. Res. Commun. 242, 238-243
189. Nakamura, Y., Morishita, R., Nakamura, S., Aoki, M., Moriguchi, A., Matsumoto, K., Nakamura, T., Higaki, J. and Ogihara, T. (1996) A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension 28, 409-413
190. Hayashi, Y., Saitoh, S., Takagi, S., Tuchihashi, K., Miura, T. and Shimamoto, K. (2002) Hepatocyte growth factor and 24-hour ambulatory blood pressure monitoring. Hypertens. Res. 25, 655-660
191. Vistoropsky, Y., Trofimov, S., Malkin, I., Kobyliansky, E. and Livshits, G. (2008) Genetic and environmental determinants of hepatocyte growth factor levels and their association with obesity and blood pressure. Ann. Hum. Biol. 35, 93-103
192. Yamamoto, Y., Kohara, K., Tabara, Y., Igase, M., Nakura, J. and Miki, T. (2002) Plasma hepatocyte growth factor and the relationship between risk factors and carotid atherosclerosis. Hypertens. Res. 25, 661-667
193. Hu, Z.P., Wang, B.N., Qian, H.Y., Zhou, Q., Wei, W. and Wang, Y. (2010) Fixed-dose telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in decreasing serum hepatocyte growth factor and improving endothelial dysfunction in hypertensive patients. Int. Heart J. 51, 252-258
194. Komai, N., Ohishi, M., Morishita, R., Moriguchi, A., Kaibe, M., Matsumoto, K., Rakugi, H., Higaki, J. and Ogihara, T. (2002) Serum hepatocyte growth factor concentration is correlated with the forearm vasodilator response in hypertensive patients. Am. J. Hypertens. 15, 499-506
195. Malatino, L.S., Cataliotti, A., Benedetto, F.A., Stancanelli, B., Bellanuova, I., Belluardo, P., Bonaiuto, L., Tripepi, G., Mallamaci, F., Castellino, P. and Zoccali, C. (2003) Hepatocyte growth factor and left ventricular geometry in end-stage renal disease. Hypertension 41, 88-92
196. Akiyama, Y., Ashizawa, N., Seto, S., Ohtsuru, A., Kuroda, H., Ito, M., Yamashita, S. and Yano, K. (1999) Involvement of receptor-type tyrosine kinase gene families in cardiac hypertrophy. J. Hypertens. 17, 1329-1337
197. Messaoudi, S., Gravez, B., Tarjus, A., Pelloux, V., Ouvrard-Pascaud, A., Delcayre, C., Samuel, J., Launay, J.M., Sierra-Ramos, C., Alvarez de la Rosa, D. et al. (2013) Aldosterone-specific activation of cardiomyocyte mineralocorticoid receptor in vivo. Hypertension 61, 361-367
198. Rychli, K., Richter, B., Hohensinner, P.J., Kariem Mahdy, A., Neuhold, S., Zorn, G., Berger, R., Mörtl, D., Huber, K., Pacher, R. et al. (2011) Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure. Heart 97, 1158-1163
199. Zhu, Y., Hojo, Y., Ikeda, U. and Shimada, K. (2000) Production of hepatocyte growth factor during acute myocardial infarction. Heart 83, 450-455
200. Matsumoto, K., Okazaki, H. and Nakamura, T. (1992) Up-regulation of hepatocyte growth factor gene expression by interleukin-1 in human skin fibroblasts. Biochem. Biophys. Res. Commun. 188, 235-243
201. Nakamura, T. and Mizuno, S. (2010) The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 86, 588-610
202. Bigatto, V., De Bacco, F., Casanova, E., Reato, G., Lanzetti, L., Isella, C., Sarotto, I., Comoglio, P.M. and Boccaccio, C. (2015) TNF-α promotes invasive growth through the MET signaling pathway. Mol. Oncol. 9, 377-388
203. Sorour, A.E., Lonn, J., Nakka, S.S., Nayeri, T. and Nayeri, F. (2015) Evaluation of hepatocyte growth factor as a local acute phase response marker in the bowel: the clinical impact of a rapid diagnostic test for immediate identification of acute bowel inflammation. Cytokine 71, 8-15